Jove
Visualize
Contact Us

Related Experiment Videos

Diaziquone (AZQ).

J F Bender, A J Grillo-Lopez, J G Posada

    Investigational New Drugs
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Diaziquone, an alkylating agent, shows promise against brain tumors due to its ability to penetrate the central nervous system. Further studies are needed in less-pretreated patients to confirm its efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evaluation of aldosterone to direct renin ratio, low renin and related Phenotypes in Afro-Colombian patients with apparent treatment resistant hypertension.

    Scientific reports·2024
    Same author

    Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
    Same author

    Kidney transplantation for end-stage renal disease in lupus nephritis, a very safe procedure: a single Latin American transplant center experience.

    Lupus·2017
    Same author

    Do you know a dyslexiac?

    The Scientific monthly·2010
    Same author

    Aptitude testing.

    The Scientific monthly·2010
    Same author

    Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.

    Leukemia & lymphoma·2006
    Same journal

    A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

    Investigational new drugs·2026
    Same journal

    Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

    Investigational new drugs·2026
    Same journal

    Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

    Investigational new drugs·2026
    Same journal

    Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes.

    Investigational new drugs·2026
    Same journal

    Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia.

    Investigational new drugs·2026
    Same journal

    Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors.

    Investigational new drugs·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Oncology
    • Pharmacology
    • Cancer Therapeutics

    Background:

    • Diaziquone is an aziridinylbenzoquinone with alkylating agent properties.
    • It exhibits broad antitumor activity in murine models, including curative effects against intracerebral tumors.

    Purpose of the Study:

    • To evaluate the pharmacokinetic profile and antitumor activity of diaziquone.
    • To assess its safety and tolerability, particularly dose-limiting toxicities.

    Main Methods:

    • Pharmacokinetic analysis including distribution and metabolism.
    • Assessment of antitumor activity in transplantable murine tumors.
    • Phase I and preliminary Phase II clinical trials in cancer patients.

    Main Results:

    Related Experiment Videos

    • Diaziquone distributes rapidly into tissues and penetrates the central nervous system effectively.
    • Myelosuppression (leukopenia, granulocytopenia, thrombocytopenia) is the primary dose-limiting toxicity.
    • Demonstrated activity against primary brain tumors in clinical trials, especially in heavily pretreated patients.

    Conclusions:

    • Diaziquone shows potential as a brain tumor therapeutic agent due to its CNS penetration and observed activity.
    • Further investigation in patients with minimal prior therapy is warranted to fully ascertain its efficacy and therapeutic window.